These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 31594236)

  • 1. Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease.
    Morsy A; Trippier PC
    J Alzheimers Dis; 2019; 72(s1):S145-S176. PubMed ID: 31594236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development.
    Ising C; Stanley M; Holtzman DM
    Clin Pharmacol Ther; 2015 Nov; 98(5):469-71. PubMed ID: 26250900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review.
    West S; Bhugra P
    Br J Clin Pharmacol; 2015 Aug; 80(2):221-34. PubMed ID: 25753046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Connecting the Dots: Linking the Biochemical to Morphological Transitions in Alzheimer's Disease.
    Baig AM
    ACS Chem Neurosci; 2019 Jan; 10(1):21-24. PubMed ID: 30160095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
    PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on drug treatment options of Alzheimer's disease.
    Allgaier M; Allgaier C
    Front Biosci (Landmark Ed); 2014 Jun; 19(8):1345-54. PubMed ID: 24896354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease.
    Cho JE; Kim JR
    Recent Pat CNS Drug Discov; 2011 Sep; 6(3):222-33. PubMed ID: 21834780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review.
    Malafaia D; Albuquerque HMT; Silva AMS
    Eur J Med Chem; 2021 Mar; 214():113209. PubMed ID: 33548635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs for Targeted Therapies of Alzheimer's Disease.
    Tam C; Wong JH; Ng TB; Tsui SKW; Zuo T
    Curr Med Chem; 2019; 26(2):335-359. PubMed ID: 29714133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.
    Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R
    J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of Disease-modifying Therapy for Alzheimer's Disease].
    Akiyama H
    Brain Nerve; 2016 Apr; 68(4):463-72. PubMed ID: 27056864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in the development of new drugs in Alzheimer's disease.
    Piau A; Nourhashémi F; Hein C; Caillaud C; Vellas B
    J Nutr Health Aging; 2011 Jan; 15(1):45-57. PubMed ID: 21267520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives.
    Suzuki N; Hatta T; Ito M; Kusakabe KI
    Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.